The traditional model of patience in biotech investing is being challenged by those who want control of a company’s remains.
By ANDREW POLLACK, NY Times: Business
Mon, 03/09/2009 - 12:44pm
The traditional model of patience in biotech investing is being challenged by those who want control of a company’s remains.